$19.89
0.00% yesterday
Nasdaq, Oct 17, 10:00 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$19.89
+1.83 10.13% 1M
-0.85 4.10% 6M
-1.72 7.96% YTD
+7.53 60.92% 1Y
+1.66 9.11% 3Y
+12.94 186.19% 5Y
+7.88 65.61% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
+0.00 0.00%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Market capitalization $1.69b
Enterprise Value $1.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 362.46
P/S ratio (TTM) P/S ratio 483.59
P/B ratio (TTM) P/B ratio 3.89
Revenue (TTM) Revenue $3.50m
EBIT (operating result TTM) EBIT $-287.99m
Free Cash Flow (TTM) Free Cash Flow $-241.20m
Cash position $425.10m
EPS (TTM) EPS $-3.38
P/E forward negative
P/S forward 53.91
EV/Sales forward 40.41
Short interest 11.95%
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
92%
Hold
8%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3.50 3.50
-
100%
- Direct Costs 0.16 0.16
67% 67%
5%
-0.16 -0.16
67% 67%
-5%
- Selling and Administrative Expenses 92 92
106% 106%
2,632%
- Research and Development Expense 199 199
57% 57%
5,696%
-288 -288
67% 67%
-8,228%
- Depreciation and Amortization 0.01 0.01
98% 98%
0%
EBIT (Operating Income) EBIT -288 -288
67% 67%
-8,228%
Net Profit -264 -264
65% 65%
-7,545%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
13 days ago
WALTHAM, Mass. , Oct. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on October 1, 2024 the Company granted inducement awards to purchase up to 62,700 shares of common stock to five new employees under the Company's 2023 Inducement Plan.
Neutral
PRNewsWire
29 days ago
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least ...
Neutral
PRNewsWire
about one month ago
WALTHAM, Mass. , Sept. 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on September 1, 2024 the Company granted an inducement award to purchase up to 60,000 shares of common stock to one new employee under the Company's 2023 Inducement Plan.
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 184
Founded 2005
Website www.syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today